458 related articles for article (PubMed ID: 17063350)
21. Urine markers for bladder cancer surveillance: a systematic review.
van Rhijn BW; van der Poel HG; van der Kwast TH
Eur Urol; 2005 Jun; 47(6):736-48. PubMed ID: 15925067
[TBL] [Abstract][Full Text] [Related]
22. The clinicopathologic correlates of cellular atypia in urinary cytology of ileal neobladders.
Cimino-Mathews A; Ali SZ
Acta Cytol; 2011; 55(5):449-54. PubMed ID: 21986173
[TBL] [Abstract][Full Text] [Related]
23. Combinations of urine-based tumour markers in bladder cancer surveillance.
Horstmann M; Patschan O; Hennenlotter J; Senger E; Feil G; Stenzl A
Scand J Urol Nephrol; 2009; 43(6):461-6. PubMed ID: 19903092
[TBL] [Abstract][Full Text] [Related]
24. [Urinary cytology in cases of bladder cancer: a critical evaluation].
Rathert P
Urologe A; 2003 Jul; 42(7):908-11. PubMed ID: 12898033
[TBL] [Abstract][Full Text] [Related]
25. Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine.
Descotes F; Kara N; Decaussin-Petrucci M; Piaton E; Geiguer F; Rodriguez-Lafrasse C; Terrier JE; Lopez J; Ruffion A
Br J Cancer; 2017 Aug; 117(4):583-587. PubMed ID: 28683471
[TBL] [Abstract][Full Text] [Related]
26. Voided urine versus bladder washing cytology for detection of urothelial carcinoma: which is better?
Keller AK; Jensen JB
Scand J Urol; 2017 Aug; 51(4):290-292. PubMed ID: 28398114
[TBL] [Abstract][Full Text] [Related]
27. Telomerase activity in urine after transurethral resection is not a predictive marker for recurrence of superficial bladder cancer.
Wu XX; Kakehi Y; Nishiyama H; Habuchi T; Ogawa O
Int J Urol; 2003 Feb; 10(2):117-8. PubMed ID: 12588612
[No Abstract] [Full Text] [Related]
28. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
Kumar A; Kumar R; Gupta NP
Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
[TBL] [Abstract][Full Text] [Related]
29. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
30. [The BTA stat test in the follow-up for bladder cancer].
Gutiérrez Baños JL; Martín García B; de Diego Rodríguez E; Hernández Rodríguez R; Portillo Martín JA; Correas Gómez MA; del Valle Schaan JI; Roca Edreira A; Rado Velázquez MA
Arch Esp Urol; 1999 Oct; 52(8):856-61. PubMed ID: 10589117
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of semaphorin 3A in patients with urothelial cancer.
Vadasz Z; Rubinstein J; Bejar J; Sheffer H; Halachmi S
Urol Oncol; 2018 Apr; 36(4):161.e1-161.e6. PubMed ID: 29288007
[TBL] [Abstract][Full Text] [Related]
32. Management of high-risk non-muscle invasive bladder cancer.
Brausi M; Olaru V
Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
[TBL] [Abstract][Full Text] [Related]
33. The clinical significance of urine cytology after a radical cystectomy for urothelial cancer.
Yoshimine S; Kikuchi E; Matsumoto K; Ide H; Miyajima A; Nakagawa K; Oya M
Int J Urol; 2010 Jun; 17(6):527-32. PubMed ID: 20370849
[TBL] [Abstract][Full Text] [Related]
34. [The value of urine phosphohexose isomerase activity in comparison with urine cytology. First diagnosis and tumor after-care in patients with cancer of the urinary bladder].
Voigt W; Rothauge CF; Schäffer R
Urologe A; 1994 May; 33(3):235-42. PubMed ID: 8053092
[TBL] [Abstract][Full Text] [Related]
35. Are cystoscopy and urinary cytology sufficient to identify candidates for subsequent biopsy after bacillus Calmette-Guérin treatment in patients with bladder carcinoma in situ?
Haase RN; Harving N
Scand J Urol; 2015; 49(4):338-40. PubMed ID: 25660358
[No Abstract] [Full Text] [Related]
36. Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma.
Lotan Y; OʼSullivan P; Raman JD; Shariat SF; Kavalieris L; Frampton C; Guilford P; Luxmanan C; Suttie J; Crist H; Scherr D; Asroff S; Goldfischer E; Thill J; Darling D
Urol Oncol; 2017 Aug; 35(8):531.e15-531.e22. PubMed ID: 28366272
[TBL] [Abstract][Full Text] [Related]
37. [Diagnosis of urothelial carcinoma].
Karl A; Zaak D; Tilki D; Hungerhuber E; Staehler M; Denzinger S; Stanislaus P; Tritschler S; Strittmatter F; Stief C; Burger M
Urologe A; 2008 Mar; 47(3):357-67. PubMed ID: 18274722
[TBL] [Abstract][Full Text] [Related]
38. Urinary modified nucleosides as novel biomarkers for diagnosis and prognostic monitoring of urothelial bladder cancer.
Zhang YR; Shi L; Wu H; Tang DD; Wang SM; Liu HM; Zhang LR; Song DK
Tumori; 2014; 100(6):660-6. PubMed ID: 25688500
[TBL] [Abstract][Full Text] [Related]
39. [Urinary cytology of transitional-cell carcinoma].
Piazza G; Galia A; Cosentino A; Grasso G
Pathologica; 1995 Apr; 87(2):146-7. PubMed ID: 8532407
[TBL] [Abstract][Full Text] [Related]
40. Clinical Decision Making in Surveillance of Non-Muscle-Invasive Bladder Cancer: The Evolving Roles of Urinary Cytology and Molecular Markers.
Zuiverloon TCM; de Jong FC; Theodorescu D
Oncology (Williston Park); 2017 Dec; 31(12):855-62. PubMed ID: 29297169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
